Loryna Kit
Product Images NDC 63629-2336

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Loryna (NDC 63629-2336). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A forest plot chart illustrating the risk of venous thromboembolism (VTE) associated with Drospirenone and Ethinyl Estradiol compared to LNG-containing combined oral contraceptives (COCs). The chart displays hazard ratios and odds ratios from various prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic case studies, with a logarithmic scale for risk ranging from 0.1 to 10.*

FDA Label Image

Figure 2 (Image 02)

A horizontal bar chart titled 'Likelihood of Developing a VTE' displaying the risk of venous thromboembolism among four groups: Non-Pregnant Non-COC users, COC users, Pregnant women, and Postpartum women (12 weeks only). The chart shows the number of women with a blood clot per 10,000 women-years, with postpartum women having the highest risk range from 40 to 65, pregnant women 5 to 20, COC users 3 to 9, and non-pregnant non-COC users 1 to 5. Pregnancy data is based on actual pregnancy duration and modeled at nine months.*

FDA Label Image

Structure Formula (Image 03)

Chemical structure diagrams of the active ingredients Drospirenone and Ethinyl Estradiol. The image shows detailed molecular structures labeled with their respective ingredient names below each structure.*

FDA Label Image

Figure (Image 04)

A diagram illustrating pregnancy rates per 100 women in one year relative to various birth control methods. It lists methods from fewest to most pregnancies: implants, injections, intrauterine devices, sterilization; birth control pills, skin patch, vaginal ring; condoms, diaphragm; no sex during fertile days, spermicide, withdrawal; and no birth control at highest pregnancy rates.*

FDA Label Image

Figure 3 (Image 06)

A horizontal bar chart depicting the likelihood of developing a serious blood clot among different groups of women per 10,000 woman-years. The groups shown are Non-Pregnant Non-COC users, COC users, Pregnant women, and Postpartum (12 weeks only), with corresponding risk ranges displayed on each bar.*

FDA Label Image

Label (Lbl636292336)

Label for LORYNA (Drospirenone and Ethinyl Estradiol Tablets, USP) showing a 3 mg/0.02 mg strength. The kit contains 84 tablets distributed as three blister cards of 28 tablets each. The label includes storage instructions, manufacturer Bryant Ranch Prepack Inc., NDC 63629-2336-1, and a warning that the package is not child resistant.*

FDA Label Image

Loryna-new-blister (Loryna New Blister)

A medication day tracker for Loryna (Drospirenone and Ethinyl Estradiol Tablets, USP 3 mg/0.02 mg), organized by week and day (Sunday to Saturday). The diagram shows empty circles representing pill dosing days for weeks 1 to 3, and shaded circles for the last four days of week 4, helping users follow daily tablet intake in a monthly cycle.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.